ANN ARBOR, Mich., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for severe, chronic cardiovascular diseases, today announced that it has been granted a U.S. patent which provides composition of matter protection for its investigational expanded autologous cell therapy product.
